Veliparib overcomes multidrug resistance in liver cancer cells |
| |
| Institution: | 1. Department of Laboratory Medicine, Bishan Hospital, Chongqing, China;2. Department of Nephrology, Bishan Hospital, Chongqing, China;1. Department of Vascular and Endocrine Surgery, Xijing Hospital, The Fourth Military Medical University, 127 Changle Western Road, Xi’an, Shaanxi Province 710032, PR China;2. Department of the Second Obstetrics and Gynecology, Tumor Hospital, Xi’an, Shaanxi Province 710061, PR China;3. State Key Laboratory of Cancer Biology & Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, 127 Changle Western Road, Xi’an, Shaanxi Province 710032, PR China;1. School of Biological Sciences, Department of Molecular & Biomedical Science, Research Centre for Infectious Diseases, University of Adelaide, Adelaide, 5005, Australia;2. Institute for Glycomics, Griffith University Gold Coast Campus, Queensland, 4222, Australia;1. Department of Biological Sciences, University of Ulsan, Ulsan, 680-749, South Korea;3. Meta-Inflammation Research Center, University of Ulsan, Ulsan, 680-749, South Korea;2. Department of Radiology, Kangbuk Samsung Hospital, Seoul, South Korea;4. Department of Surgery, Ulsan University Hospital, University of Ulsan, Ulsan, South Korea;1. Department of Human Nutrition, Faculty of Contemporary Life Science, Chugokugakuen University, Okayama, Japan;2. Department of Microbiology, Kawasaki Medical School, Kurashiki, Japan;3. Laboratory of Gene Regulation Study, Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan;1. Department of Cardiovascular Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China;2. Department of Anesthesiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China |
| |
| Abstract: | Overexpression of ATP-binding cassette (ABC) transporter is one of the most important factors taking responsibility for the progress of multidrug resistance (MDR) in multiple cancers. In this study, we investigated that veliparib, a PARP inhibitor which is in clinical development, could overcome ABCB1-mediated MDR in liver cancer cells. Veliparib could significantly enhance the cytotoxic effects of a series of conventional chemotherapeutic drugs in ABCB1-overexpression liver cancer cells. Mechanism study showed that veliparib could significantly enhance the accumulation of doxorubicin in ABCB1-overexpression liver cancer cells, without down-regulating the expression level of ABCB1. Finally, veliparib could significantly inhibit the ATPase activity of ABCB1 transporter. This study could provide information that combine veliparib with other chemotherapeutic drugs may benefit liver cancer patients. |
| |
| Keywords: | Veliparib Liver cancer Multidrug resistance (MDR) ABC transporter |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
